✦ LIBER ✦

Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141)

✍ Scribed by Deuffic-Burban, Sylvie; Schwarzinger, Michaël; Obach, Dorothée; Mallet, Vincent; Pol, Stanislas; Pageaux, Georges-Philippe; Canva, Valérie; Deltenre, Pierre; Roudot-Thoraval, Françoise; Larrey, Dominique; Dhumeaux, Daniel; Mathurin, Philippe; Yazdanpanah, Yazdan

Book ID: 121532041
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 704 KB
Volume: 61
Category: Article
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2014.03.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O85 SHOULD WE AWAIT INTERFERON-FREE REGI

O85 SHOULD WE AWAIT INTERFERON-FREE REGIMENS TO TREAT HCV GENOTYPE 1 TREATMENT-NAIVE PATIENTS? A COST-EFFECTIVENESS ANALYSIS (ANRS 12188)

✍ Deuffic-Burban, S.; Schwarzinger, M.; Obach, D.; Mallet, V.; Pol, S.; Pageaux, G 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 58 KB

809 IMMEDIATE OR DELAYED TREATMENT INITI

809 IMMEDIATE OR DELAYED TREATMENT INITIATION WITH “PREVIR” CONTAINING REGIMENS IN HCV-INFECTED NAIVE GENOTYPE 1 (G1) PATIENTS WITHOUT SEVERE FIBROSIS? A COST-EFFECTIVENESS ANALYSIS (ANRS N°12188)

✍ Deuffic-Burban, S.; Schwarzinger, M.; Mallet, V.; Pol, S.; Pageaux, G.-P.; Canva 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 133 KB